Cloud-clone
SKU(재고 관리 코드):LML178Ra
Magnetic Luminex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc.
Magnetic Luminex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc.
Product No.
LML178Ra
Organism Species
Rattus norvegicus (Rat).
Sample Type
Serum, plasma, tissue homogenates, cell lysates and other biological fluids.
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.03-30ng/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.01 ng/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc..
No significant cross-reactivity or interference between Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 87-97 | 93 |
| EDTA plasma(n=5) | 97-104 | 101 |
| heparin plasma(n=5) | 91-98 | 94 |
| sodium citrate plasma(n=5) | 79-90 | 85 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-96% | 83-101% | 94-103% | 98-105% |
| EDTA plasma(n=5) | 97-104% | 92-105% | 89-96% | 94-101% |
| heparin plasma(n=5) | 83-90% | 89-101% | 83-105% | 97-105% |
| sodium citrate plasma(n=5) | 94-102% | 90-97% | 89-101% | 88-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:AGGF1) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease | Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma Pubmed:24462738 |
| Cancer Management and Research | IL-17 induces macrophages to M2-like phenotype via NF-κB Pubmed: 30323677 |
| Cellular Physiology and Biochemistry | Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line Pubmed: 30562734 |
| Catalog No. | Related products for research use of Rattus norvegicus (Rat) Organism species | Applications (RESEARCH USE ONLY!) |
| RPL178Ra01 | Recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAL178Ra01 | Polyclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) | WB; IHC; ICC; IP. |
| MAL178Ra21 | Monoclonal Antibody to Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) | WB; IHC; ICC; IP. |
| SEL178Ra | ELISA Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LML178Ra | Magnetic Luminex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. | Magnetic Luminex Assay for Antigen Detection. |
Share
